The effect of treatment on urinary prostanoid levels
The urinary excretion of (A) PGI2, (B) TXA2 and (C) PGF2α as measured by their metabolites, 6-keto-PGF1α, TXB2, and 8-iso-PGF2α, respectively, and (D) PGE2 and (E) its metabolite, PGE-M, following treatment with vehicle, sunitinib (14 mg/kg/day; SU) alone or during co-treatment with low-dose aspirin (COX-1 inhibition, 5 mg/kg/day; SU+low-dose A) or high-dose aspirin (dual COX-1 and COX-2 inhibition, 100 mg/kg/day; SU+high-dose A) in WKY rats. Data are presented as mean ± SEM (n=5–7/group). Data were analysed using a one-way ANOVA followed by post-hoc t tests with Holm–Sidak’s correction where appropriate. *P<0.05, **P<0.01, ***P<0.001 versus vehicle-treated.